Immune checkpoint inhibitors (ICI) (i.e., inhibitors of PD-1/PD-L1 and CTLA-4) are a class of immunotherapy that have been highly successful in treating lung cancer and have become an important part of the lung cancer treatment algorithm. This evidence concerns the gene CTLA4 and lung carcinoma.